Panoptes Pharma

Panoptes is a privately held clinical-stage biotechnology company dedicated to developing small molecule-based therapies for the treatment of serious eye diseases and addressing unmet medical needs. Headquartered in the heart of Vienna, Austria, Panoptes has successfully advanced two drug products, PaniJect and PaniDrop, since its founding in 2013. Both products are currently under clinical investigation for the treatment of severe ocular conditions with high unmet medical needs. Panoptes boasts an experienced team of development experts with a proven track record in the innovation, development, and commercialization of novel products. The company aims to achieve future growth by reaching key developmental milestones and forming strategic partnerships with leading pharmaceutical companies. By combining our proprietary technology with cost-effective development strategies, we believe this approach will pave the way for rapid and predictable commercialization, offering the potential to deliver much-needed therapies to a broader patient population.